Processa Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stockholders??? Equity (Details Narrative)

Stockholders’ Equity (Details Narrative) - USD ($)					12 Months Ended
Stockholders’ Equity (Details Narrative) - USD ($)	Feb. 14, 2023	Mar. 29, 2022	Mar. 23, 2022	Oct. 06, 2020	Dec. 31, 2023	Dec. 31, 2022	Nov. 18, 2023	Jun. 27, 2023	Apr. 17, 2023
Class of Stock [Line Items]
Preferred stock, shares issued					0	0
Preferred stock, shares outstanding					0	0
Authorized shares of common stock					100,000,000	50,000,000		100,000,000
Proceeds from Issuance of Common Stock					$ 6,321,470
Share issued value					$ (30,607)
Repurchase of common stock value						$ 300,000
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Number of shares, forfeited					12,296	3,431
Restricted Stock Units (RSUs) [Member] \| Federal, State and Local [Member]
Class of Stock [Line Items]
Number of shares, forfeited						1,809
Restricted Stock [Member]
Class of Stock [Line Items]
Number of shares, forfeited					1,250	1,676
Director [Member] \| Restricted Stock [Member]
Class of Stock [Line Items]
Number of shares, forfeited						911
Aposense, Ltd. [Member]
Class of Stock [Line Items]
Number of repurchase of common stock, shares		5,000
Repurchase of common stock value		$ 300,000
Sales Agreement [Member]
Class of Stock [Line Items]
Stock issued					28,483
Share price					$ 24.40
Gross proceeds from issuance of common stock					$ 693,000
Proceeds from Issuance of Common Stock					$ 672,000
Purchase Agreement [Member] \| Lincoln Park Capital Fund LLC [Member]
Class of Stock [Line Items]
Stock issued					2,500
Share price					$ 21.60
Gross proceeds from issuance of common stock					$ 54,000
Reimbursement fees			$ 25,000
Number of shares issued			6,181
Number of common stock issued on commitment fees, value			$ 450,000
Purchase Agreement [Member] \| Lincoln Park Capital Fund LLC [Member] \| Maximum [Member]
Class of Stock [Line Items]
Share price			$ 120.00
Number of common stock shares in regular purchase			1,250
Number of common stock shares exceeding regular purchase			3,750
Share issued value			$ 150,000
Daily maximum committed purchase obligations, value			$ 1,250,000
Maximum number of shares sold			157,122
Nasdaq's exchange cap percent			19.99%
Beneficial ownership limitation percentage			9.99%
Purchase Agreement [Member] \| Lincoln Park Capital Fund LLC [Member] \| Minimum [Member]
Class of Stock [Line Items]
Minimum closing sale price			$ 1.00
Securities Purchase Agreement [Member] \| Registered Direct Offering [Member] \| Accredited Investor [Member]
Class of Stock [Line Items]
Stock issued	390,628
Share price	$ 16.00
Gross proceeds from issuance of common stock	$ 6,300,000
Proceeds from Issuance of Common Stock	$ 5,600,000
Securities Purchase Agreement [Member] \| Registered Direct Offering [Member] \| Placement Agent [Member]
Class of Stock [Line Items]
Cash fee percentage	8.00%
Reimbursement fees	$ 60,000
Consulting Agreement [Member]
Class of Stock [Line Items]
Purchase of warrants, shares							7,500
Warrant exercise price							$ 7.40
Consulting Agreement [Member] \| Spartan Capital Securites LLC [Member]
Class of Stock [Line Items]
Purchase of warrants, shares									158,007
Warrant exercise price									$ 20.40
License Agreement [Member] \| Elion Oncology [Member]
Class of Stock [Line Items]
Shares issued in connection with license agreement						5,000
License Agreement [Member] \| Aposense, Ltd. [Member]
Class of Stock [Line Items]
Shares issued in connection with license agreement				31,250
Common Stock [Member]
Class of Stock [Line Items]
Stock issued					421,611
Number of shares issued						6,181
Share issued value					$ 6
Shares issued in connection with license agreement						5,000
Repurchase of common stock value